Subscribe today to receive notice of our latest thought leadership, articles, and updates.
Insights
Blogs
Sharing perspectives leads to greater understanding and fuels innovation
Check out our latest blog posts:
|
August 16, 2023 · Public Policy & Regulatory Affairs Team
Brief postings include proposed updates to California DWC medical treatment guidelines and the Michigan Supreme Court rules on retro-applicability of certain auto no-fault fee schedule provisions. Read more... |
|
August 11, 2023 · Clinical Team
FDA approves additional over-the-counter naloxone products Read more... |
|
|
July 26, 2023 · Public Policy & Regulatory Affairs Team
Brief updates include changes to work comp evaluating physician fees in New Jersey; updates to Tennessee work comp inpatient hospital fee schedule, medical payment regulations, and medical fee schedule rules; and adopted New York PBM regulations. Read more... |
|
|
July 18, 2023 · Clinical Team
The 2Q 2023 Brand-Generic Pipeline update Read more... |
|
|
July 06, 2023 · Clinical Team
Extended-release Brixadi has been approved by the FDA for subcutaneous injection in patients recovering from Opioid Use Disorder as part of their treatment plan. Read more... |
|
|
July 05, 2023 · Public Policy & Regulatory Affairs Team
Brief updates include Connecticut’s expansive PTSD bill, revised Montana workers’ comp treatment guidelines, proposed Arizona Industrial Commission fee schedule changes, New York adopts changes to WC telehealth, and proposed Colorado workers’ comp rule changes that would further limit physician dispensing. Read more... |
|
|
June 15, 2023 · Public Policy & Regulatory Affairs Team
News briefs on Florida physician dispensing rules update, California proposed workers’ comp treatment guideline updates and recently signed Minnesota Workers Compensation Advisory Council legislation Read more... |
|
|
May 24, 2023 · Public Policy & Regulatory Affairs Team
Brief updates include Michigan proposed workers’ comp health care services rules changes and expansion to Montana and Washington workers’ comp presumption laws Read more... |
|
|
May 08, 2023 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Teva Pharmaceuticals USA voluntarily recalled specific lots of various strengths of fentanyl buccal tablets at the consumer level. Read more... |
|
|
May 04, 2023 · Public Policy & Regulatory Affairs Team
Brief updates include Michigan auto fee schedule CPI adjustment and Montana proposed updates to work comp treatment guidelines and formulary. Read more... |
|
|
May 02, 2023 · Clinical Team
On March 29, 2023, the U.S. Food and Drug Administration (FDA) approved Narcan® (naloxone hydrochloride) 4 mg Nasal Spray for over-the-counter (OTC), nonprescription, use. Read more... |
|
|
May 01, 2023 · Clinical Team
Akorn Operating Company LLC filed Chapter 7 bankruptcy and the company has ceased all operations, including the discontinuation of the quality activities of these marketed drug products. Read more... |
Page 5 of 8
